You are here:Home-Chemical Inhibitors & Agonists-Epigenetics-Sirtuin -FLS-359
FLS-359

Chemical Structure : FLS-359

CAS No.: 2309398-79-4

FLS-359 (FLS359, FLS 359)

Catalog No.: PC-21014Not For Human Use, Lab Use Only.

FLS-359 (FLS-359) is a selective, allosteric inhibitor of sirtuin 2 (SIRT2) deacetylase activity with IC50 of 3 uM, shows no activity against SIRT1 and SIRT3, exhibits broad-spectrum antiviral activity.

Packing Price Stock Quantity
50 mg Get quote
100 mg Get quote
200 mg Get quote
1 g Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC)

Biological Activity

FLS-359 (FLS-359) is a selective, allosteric inhibitor of sirtuin 2 (SIRT2) deacetylase activity with IC50 of 3 uM, shows no activity against SIRT1 and SIRT3, exhibits broad-spectrum antiviral activity.
FLS-359 is not competitive with NAD+, FLS-359 is substrate selective, inhibiting deacetylation but not demyristoylation.
FLS-359 induces degradation of c-Myc protein in MDA-MB-231 breast adenocarcinoma cells.
FLS-359 binds selectively to SIRT2 and induces an allosteric rearrangement of the active site, reducing the rate of deacetylation.
FLS-359 shows activity against multiple RNA and DNA viruses in cultured cells (SARS-CoV-2/human Calu3, IC50=0.3 uM; HCMV/human MRC-5, IC50=0.5 uM).
FLS-359 markedly reduces EBV lytic activation in Akata cells, inhibitsthe accumulation of viral immediate-early (BZLF1), early (BMRF1), and late (BLLF1) mRNAs.
FLS-359 inhibits HCMV spread in diploid fibroblasts, inhibits the accumulation of intracellular HCMV RNAs and DNA and reduces the infectivity of virus progeny.
FLS-359 (50 mg/kg, p.o., b.i.d.) inhibits HCMV infection in humanized models of HCMV infection.

Physicochemical Properties

M.Wt 466.61
Formula C27H26N6S
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

CC1=CN(C2=CC3=C(C=C2)CCN(C4=NC=C(CC5=CC=C(N6N=CC=C6)C=C5)S4)C3)C(C)=N1

References

1. Kathryn L Roche, et al. J Clin Invest. 2023 Jun 15;133(12):e158978.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: